Skip to main content

Advertisement

Fig. 3 | Acta Neuropathologica Communications

Fig. 3

From: Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer’s disease

Fig. 3

Soluble Aβ oligomers inhibit hippocampal LTP. (a) Insoluble amyloid plaque cores from AD cortex fail to inhibit the LTP (red), while LTP was inhibited if an equivalent aliquot of the cores was solubilized in 88% formic acid and neutralized with NaOH (blue). (b) The void volume fraction of a Superdex 75 SEC chromatography of an AD cortex TBS extract (red) showed no significant LTP inhibition, but incubating the void volume fraction at 37 °C for 2 days released lower MW soluble Aβ oligomers that significantly impaired LTP (blue). (c) Summary LTP data of the indicated AD brain fractions (n = 6~ 8). (d) Representative western blot shows different MW SEC fractions of soluble Aβ-rich AD cortical extracts; (e) Oxidized synthetic [Aβ40-S26C]2 dimers (blue diamonds) cause significant LTP inhibition but monomeric Aβ1–40 does not (red); (f) Dose-dependent LTP inhibition by oxidized synthetic [Aβ40-S26C]2 dimers (red), and dityrosine cross-linked Aβ1–40 dimers (DiY) (blue). *: p < 0.05; **: p < 0.01

Back to article page